Cargando…

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease

BACKGROUND: Nilotinib is US Food and Drug Administration–approved for leukemia, and this open‐label study investigated the safety, tolerability, and potential clinical effects of nilotinib in medically optimized patients with Parkinson's disease. OBJECTIVES: Safety and tolerability were the pri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pagan, Fernando L., Wilmarth, Barbara, Torres‐Yaghi, Yasar, Hebron, Michaeline L., Mulki, Sanjana, Ferrante, Dalila, Matar, Sara, Ahn, Jaeil, Moussa, Charbel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048914/ https://www.ncbi.nlm.nih.gov/pubmed/33215762 http://dx.doi.org/10.1002/mds.28389

Ejemplares similares

Safety, target engagement, and biomarker effects of bosutinib in dementia with Lewy bodies
por: Pagan, Fernando L., et al.
Publicado: (2022)

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial
por: Pagan, Fernando. L., et al.
Publicado: (2020)

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease
por: Turner, Raymond S., et al.
Publicado: (2020)

CSF MicroRNAs Reveal Impairment of Angiogenesis and Autophagy in Parkinson Disease
por: Fowler, Alan J., et al.
Publicado: (2021)

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
por: Pagan, Fernando, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease
por: Pagan, Fernando L., et al.
Publicado: (2019)

4564 Nilotinib alters microRNAs that regulate specific autophagy and ubiquitination genes in the cerebrospinal fluid of Parkinson’s patients
por: Fowler, Alan, et al.
Publicado: (2020)

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients
por: Anderson, Karen E., et al.
Publicado: (2022)

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer’s disease
por: Stevenson, Max, et al.
Publicado: (2023)

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease
por: Moussa, Charbel, et al.
Publicado: (2017)

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration
por: Hebron, Michaeline, et al.
Publicado: (2015)

Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in α-Synucleinopathy
por: Hebron, Michaeline L., et al.
Publicado: (2014)

Tau deletion impairs intracellular β-amyloid-42 clearance and leads to more extracellular plaque deposition in gene transfer models
por: Lonskaya, Irina, et al.
Publicado: (2014)

Sialorrhea in Parkinson’s Disease
por: Isaacson, Jonathan, et al.
Publicado: (2020)

Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Tyrosine kinase inhibition increases functional parkin-Beclin-1 interaction and enhances amyloid clearance and cognitive performance
por: Lonskaya, Irina, et al.
Publicado: (2013)

Novel Ubiquitin Specific Protease-13 Inhibitors Alleviate Neurodegenerative Pathology
por: Liu, Xiaoguang, et al.
Publicado: (2021)

Fractalkine Mediates Communication between Pathogenic Proteins and Microglia: Implications of Anti-Inflammatory Treatments in Different Stages of Neurodegenerative Diseases
por: Desforges, Nicole M., et al.
Publicado: (2012)

QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review
por: Torres-Yaghi, Yasar, et al.
Publicado: (2021)

Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
por: Pahwa, Rajesh, et al.
Publicado: (2022)

Correction to: Screening, Diagnosis, and Management of Parkinson’s Disease Psychosis: Recommendations From an Expert Panel
por: Pahwa, Rajesh, et al.
Publicado: (2023)

Inhibition of Ubiquitin-Specific Protease-13 Improves Behavioral Performance in Alpha-Synuclein Expressing Mice
por: Liu, Xiaoguang, et al.
Publicado: (2022)

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
por: Fowler, Alan J., et al.
Publicado: (2019)

Allogeneic Bone Marrow–Derived Mesenchymal Stem Cell Safety in Idiopathic Parkinson's Disease
por: Schiess, Mya, et al.
Publicado: (2021)

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease
por: Quattrone, Andrea, et al.
Publicado: (2022)

The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022)

Nilotinib in Parkinson's disease: A systematic review and meta-analysis
por: Xie, Xiaolu, et al.
Publicado: (2022)

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
por: Heilman, Patrick L., et al.
Publicado: (2020)

Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource
por: Iwaki, Hirotaka, et al.
Publicado: (2021)

Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk
por: Lake, Julie, et al.
Publicado: (2021)

Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics
por: Bandres‐Ciga, Sara
Publicado: (2022)

Nigral Neurons Degenerating in Parkinson's Disease Express the Angiotensin Receptor Type 1 Gene
por: Labandeira‐Garcia, Jose L., et al.
Publicado: (2022)

The Parkinson's Disease DNA Variant Browser
por: Kim, Jonggeol J., et al.
Publicado: (2021)

Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

The Myelin‐Weighted Connectome in Parkinson's Disease
por: Boshkovski, Tommy, et al.
Publicado: (2021)

International Multicenter Analysis of Brain Structure Across Clinical Stages of Parkinson's Disease
por: Laansma, Max A., et al.
Publicado: (2021)

Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease
por: Onofrj, Marco, et al.
Publicado: (2021)

Reply to: “Association between Microscopic Colitis and Parkinson's Disease in a Swedish Population”
por: Kang, Xiaoying, et al.
Publicado: (2021)

Usability of the Experience Sampling Method in Parkinson's Disease on a Group and Individual Level
por: Mulders, Anne E.P., et al.
Publicado: (2020)

Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
por: Vila, Miquel
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_d5gaufif8d0nejggb1s1o0r7qp